Cardiovascular diseases (CVD) remain the leading cause of global mortality, accounting for one in every two adult deaths worldwide. The rates of CVD-related morbidity, including heart-failure, peripheral arterial disease and nephropathy are increasing as more patients survive hearts attacks, and the population ages. In addition, Metabolic Diseases, specifically Type 2 diabetes (T2D) and obesity, are major health problems that have reached epidemic proportions worldwide. Globally T2D and obesity incidence have more than doubled in the past two decades. Importantly, CVD and T2D impose large economic burdens on the individual patient and on national healthcare systems and economies. Pfizer scientists are eager to work with world-class partners who share our mission to develop novel and differentiated medicines to improve the lives of patients suffering from CVD.
Pfizer is interested in partnering to develop therapeutics, expand our understanding of disease biology, and identify biomarkers that can help us impact:
- CVD (Heart failure, hypertriglyceridemia, atherosclerosis)
- Type 2 diabetes and related disorders such as hyperinsulinemia
- Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), and liver cirrhosis
- Cachexia as a consequence of chronic illness
- Obesity and related co-morbidities
- Chronic kidney disease, diabetic kidney disease, and polycystic kidney disease
- Vascular disease
Specific areas of interest include:
- Metabolic treatments of heart failure (HFrEF, HFpEF)
- Novel therapies that target insulin sensitivity in type 2 diabetes
- Addressing obesity and eating disorders to induce and sustain weight loss
- New mechanisms and pathways for the treatment of diabetic nephropathy, chronic kidney disease or polycystic kidney disease
- Novel approaches to target vascular dysfunction
Not actively seeking partnering opportunities in:
- Anti-arrhythmics
- Stable angina treatments